Eugenol cytotoxicity evaluated with continuous cell lines.

Toxicol In Vitro

Stern College for Women, Yeshiva University, Department of Biological Sciences, 245 Lexington Avenue, New York, NY 10016, USA.

Published: March 1993

The cytotoxicity of eugenol to replicating cells, as mediated by the intracellular level of glutathione and by metabolic activation, was evaluated with the neutral red (NR) assay. The cytotoxicity of eugenol to human HFF fibroblasts and human HepG2 hepatoma cells was increased somewhat in the presence of a hepatic S-9 microsomal fraction from Aroclor-induced rats or hamsters. Exposure of human HepG2 hepatoma cells to eugenol depleted the level of intracellular glutathione. Cells treated with 1-chloro-2,4-dinitrobenzene (CDNB) or buthionine sulphoximine (BSO), agents that deplete intracellular glutathione, were hypersensitive to eugenol. A 1-hr pretreatment with CDNB enhanced the cytotoxicity of eugenol, as did a 24-hr pretreatment with BSO. Intracellular glutathione levels were, apparently, significant in mediating the toxicity of eugenol.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0887-2333(93)90119-pDOI Listing

Publication Analysis

Top Keywords

cytotoxicity eugenol
12
intracellular glutathione
12
human hepg2
8
hepg2 hepatoma
8
hepatoma cells
8
eugenol
7
eugenol cytotoxicity
4
cytotoxicity evaluated
4
evaluated continuous
4
continuous cell
4

Similar Publications

Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy.

Biomed Pharmacother

January 2025

Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno CZ-61200, Czech Republic; Department of Biophysics, Faculty of Science, Palacky University, Slechtitelu 27, Olomouc 783 71, Czech Republic. Electronic address:

Platinum(IV) compounds possess distinct properties that set them apart from platinum(II) compounds. Often designed as prodrugs, they are reduced within cancer cells to their active platinum(II) form, enabling their cytotoxic effects. Their versatility also lies in their ability to be functionalized and conjugated with bioactive molecules to enhance cancer cell targeting.

View Article and Find Full Text PDF

The current study proposes the in vitro and in silico anticancer evaluation of clove ( L.) essential oil (CEO). The steam hydrodistillation method used yielded 10.

View Article and Find Full Text PDF

Chagas disease (CD) is a life-threatening illness caused by the protozoan Trypanosoma cruzi and there are only two drugs currently available for pharmacotherapy of this neglected infection (benznidazole and nifurtimox). Their limited efficacy in chronic phase of the disease, problems of toxicity and the growing resistance by the protozoan are directly associated to high rates of drug discontinuation by the patients. In the context of the search for new trypanocidal drug candidates, our group has been working with the chemical manipulation of eugenol to obtain new agents active against T.

View Article and Find Full Text PDF

Background: is a protozoan parasite responsible for canker in pigeons, a debilitating disease that causes significant economic losses. While metronidazole (MTZ) remains the primary treatment, the emergence of resistance is a growing concern. This study investigated the efficacy of eugenol and its nanoemulsion formulation against in both and settings.

View Article and Find Full Text PDF
Article Synopsis
  • Nearly half of the global population is affected by an infection, with current treatments involving antibiotics and proton pump inhibitors; however, rising antimicrobial resistance remains a major issue.
  • Phenolic monoterpenes like eugenol, vanillin, carvacrol, and thymol are of interest for their biological activities and potential for easy modifications, leading to the creation of mono- and bis-azo derivatives through aryl diazotization.
  • The synthesized compounds were tested against various bacterial strains, revealing some effective inhibitors and subsequently underwent cytotoxicity evaluations and target investigations using structure-based docking calculations on key pharmacological targets.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!